-

VectorY to Present a Poster at the European Network to Cure ALS (ENCALS) Annual Meeting

AMSTERDAM--(BUSINESS WIRE)--VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, today announces presentation of a poster at the European Network to Cure ALS (ENCALS) Annual Meeting at the University of Edinburgh on 1-3 June, 2022.

Members of the VectorY team will attend the conference in person and will be available to discuss the poster.

The details of the poster can be found below:

  • VecTabs: Selective targeting of protein aggregates and oxidized phospholipids for the treatment of Amyotrophic Lateral Sclerosis – Marina Sogorb-Gonzalez, et al. Wednesday 1 June 2022, McEwan Hall, d114

To meet the team, please contact info@vectorytx.com.

ENDS

Notes to Editors

About VectorY
VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for neurodegenerative and -muscular diseases with high unmet medical need. Founded in October 2020 and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics based on a novel AAV gene therapy platform, antibody-based targeted protein degradation technologies and proprietary manufacturing technology. While focusing initially on neurodegenerative and -muscular diseases, VectorY's synergistic technologies may be applied across a wide range of indications. VectorY’s manufacturing capabilities will include a state-of-the-art multi-product GMP facility in the Netherlands.

For more information, see www.vectorytx.com.

Contacts

For further information, please contact:

VectorY B.V.
Alexander Vos, CEO
Tel: ++31 (20) 226 8020
Instinctif Partners (media enquiries)
Melanie Toyne-Sewell / Katie Duffell
E-mail: VectorY@instinctif.com
Tel: +44 20 7457 2020

Industry:

VectorY

Release Versions
English

Contacts

For further information, please contact:

VectorY B.V.
Alexander Vos, CEO
Tel: ++31 (20) 226 8020
Instinctif Partners (media enquiries)
Melanie Toyne-Sewell / Katie Duffell
E-mail: VectorY@instinctif.com
Tel: +44 20 7457 2020

More News From VectorY

VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS

AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company to proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002. VTx-002 is a first-in-class vectorized antibody targeting TDP-43 pathology in amyotrophic lateral sclerosis (ALS). TDP-43 pathology drives up to 97 percent of ALS cases. VTx-002, VectorY’s lead vectorized antibody pro...

VectorY Appoints Seasoned Biotech Leader Adam Rosenberg as Chair of the Board

AMSTERDAM--(BUSINESS WIRE)--VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Adam Rosenberg as the new Chair of the Board. Boston-based Mr Rosenberg brings over 20 years of experience in building and leading life sciences companies, primarily in the neuroscience space. He replaces Dr Carlo Incerti who is stepping down from the company’s board. The appointment comes at a pivot...

UMC Utrecht and VectorY Therapeutics collaborate in ALS Biomarker Study

UTRECHT, Netherlands & AMSTERDAM--(BUSINESS WIRE)--UMC Utrecht has enrolled its first patient for a new study to identify biomarkers of Amyotrophic Lateral Sclerosis (ALS). The observational investigator-initiated study is led by Professor Dr. Leonard van den Berg and supported by VectorY Therapeutics. VectorY Therapeutics is developing innovative vectorized antibody therapies for neurodegenerative diseases. VectorY’s lead program, VTx-002, is targeting TDP-43 for the treatment of ALS. ALS is a...
Back to Newsroom